A Chinese cancer drug maker that has not been inspected by the FDA since 2018 is selling chemotherapy drugs to the U.S. due to shortages. When will the U.S. meet its critical medication needs?
The balance between scarcity and supply favors supply, even if that means importing drugs from labs the FDA has not inspected.
At a recent House Ways & Means subcommittee hearing on trade, CEO Michael Stumo talks de minimis, and the inescapable realities of China’s forced labor.
The following written testimony was submitted by Michael Stumo, CEO of CPA, to the House Ways and Means Subcommittee on Trade for a hearing titled,
The U.S. is increasingly reliant on imported drugs from uninspected labs. It’s not safe. What can be done about it?
The following written testimony was submitted to the Congressional-Executive Commission China (CECC) on April 18, 2023 by CPA’s Robby Stephany Saunders, Vice President for National
A Senate hearing on pharmaceutical shortages discusses America’s dependence on India and China, and what can be done to reshore.
The Senate Commerce Committee takes the little known, and even less understood, Pharmacy Benefit Manager industry to task for high drug costs.
What are the risks China poses to the U.S. industrial supply chain and what can be done about it? Some quotes from Congress and witnesses from a Feb. 7 hearing.
The U.S. is increasingly dependent on imports for drugs. One reason: a tax avoidance scheme that pits U.S. manufacturing up against Europe. What can be done about this problem?
